Eloxx Pharmaceuticals Reports $3.8 Million Net Loss in Q1 2026, Sees Surge in Operating Expenses

Eloxx Pharmaceuticals, Inc. reported a net loss of $3.8 million for the first quarter of 2026, a significant increase from the $1.7 million loss recorded in the same period of 2025. The company's total operating expenses surged to $3.8 million, up 211% from $1.2 million year-over-year. This increase was primarily driven by a 225% rise in research and development expenses, which reached $1.7 million, and a 200% increase in general and administrative expenses, totaling $2.1 million. The company has not generated revenue from product sales, relying instead on limited license and collaboration agreements.

In terms of financial position, Eloxx's cash and cash equivalents increased to $6.4 million as of March 31, 2026, compared to $4.8 million at the end of 2025. The company’s total assets also rose to $8.5 million from $5.3 million, while total liabilities decreased slightly to $16.1 million from $17.2 million. The stockholders' deficit improved to $7.6 million from $11.9 million, reflecting the issuance of new shares and pre-funded warrants as part of financing activities. Eloxx's employee headcount remains stable, with no significant changes reported.

Strategically, Eloxx has focused on advancing its lead product candidate, exaluren, which is in clinical development for treating rare kidney diseases. The company has received clearance to initiate a Phase 2b clinical trial for exaluren in patients with nonsense mutations associated with Alport Syndrome, expected to begin in the first half of 2026. Additionally, Eloxx has licensed its product candidate ZKN-013 to Almirall, S.A., which is developing it for rare skin diseases. The agreement includes potential milestone payments and royalties, although the company has not yet realized significant revenue from this partnership.

Looking ahead, Eloxx acknowledges the need for substantial additional funding to support its operations and product development efforts. The company has expressed concerns regarding its ability to continue as a going concern, given its history of operating losses and the uncertainty surrounding its ability to raise capital. Management plans to pursue various financing options, including public or private debt and equity transactions, to ensure sufficient liquidity for ongoing operations. The company anticipates that it may take several years before it can achieve profitability, contingent upon successful clinical trials and regulatory approvals for its product candidates.